Credit: IMBA/Tibor Kulcsar

UBC scientist discovers trial drug that can significantly block early stages of COVID-19 in engineered human tissues

Posted on

An international team led by UBC researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts. The findings hold promise as a treatment capable of stopping early infection of the novel coronavirus.

“We are hopeful our results have implications for the development of a novel drug for the treatment of this unprecedented pandemic,” says Penninger, professor in UBC’s faculty of medicine, director of the Life Sciences Institute and the Canada 150 Research Chair in Functional Genetics at UBC….

https://news.ubc.ca/2020/04/02/ubc-led-study-finds-trial-drug-can-significantly-block-early-stages-of-covid-19-in-engineered-human-tissues/

Read More Impact Stories

Posted on
McGill-developed device offers 100 per cent accuracy in as little as 10 minutes, and can be configured to detect a [...]
Posted on
This content is available in French only.
Posted on
The University of Toronto and Moderna, Inc. known for its mRNA-based COVID-19 vaccine plan to work together to develop new [...]